Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up study of Kite gene-modified cell therapy recipients
NL-OMON58848Phase 2Recruiting
- Sponsor
- Kite Pharma
- Start
- Nov 2022
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of axicabtagene ciloleucel in Non-hematologic malignancy and hematopoietic malignancies, sponsored by Kite Pharma. Primary endpoints: Late-onset neurologic disorders, Late-onset autoimmune disorders and 4 more. Started Nov 2022; status: recruiting.
02
Drugs
axicabtagene ciloleucel
03
Conditions
Non-hematologic malignancyhematopoietic malignancies
Beyond the preview
Go deeper on NL-OMON58848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58848.